overgeneralization ???? [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2013-02-21 13:17 (4862 d 11:09 ago) – Posting: # 10091
Views: 10,252

Hi Luv,

❝ ❝ Worst: A strong tendency to bend the rules (“make” analytical batches valid, dealing with outliers, etc.).


❝ […] Now coming to the rules/guidance (except “make” analytical batches valid, dealing with outliers) aren't they non binding recomendations :cool:.


Of course they are – I make my money dealing with problems which are generally non-standard. I meant intentionally deviating from GLs – without justifications, not searching scientific advice, etc. Simply bending the rules hoping for not being discovered. There is a fine line between thoughtlessness and fraud.

❝ We have followed the same in our protocols and till now not received any query on the same (blame it to 30 minute review window)


Oh, I always thought it is one hour?

❝ FDA prefers the same thing, got some queries on the same and was suggested to do it the EMEA way.


What – exactly – do you mean by “the EMEA way”?

❝ Now how about ER/MR/XR formulations as per the current guidelines??? 2 times median Tmax or τ (dosing interval)?


I use the dosing interval. Was too lazy now to look it up in GLs.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
119 visitors (0 registered, 119 guests [including 11 identified bots]).
Forum time: 01:26 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5